Nesiritide and worsening of renal function: The emperor's new clothes?

Circulation

Volumn 111, Issue 12, 2005, Pages 1459-1461

  Teerlink, John R ^a   Massie, Barry M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Drug approval; Editorials; Heart failure; Kidney; Natriuretic peptides

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NESIRITIDE; VASODILATOR AGENT;

CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; NEPHROTOXICITY; PEER REVIEW; PRIORITY JOURNAL; PROGNOSIS;

DRUG APPROVAL; DRUG EVALUATION; DRUG LABELING; HEART FAILURE, CONGESTIVE; HUMANS; INFORMATION DISSEMINATION; KIDNEY FAILURE; NATRIURETIC PEPTIDE, BRAIN; TREATMENT OUTCOME;

EID: 16344371647     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000160874.48045.54     Document Type: Editorial

References (17)

1. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487-1491.
2. Gottlieb SS, Abraham W, Butler J, Forman DE, Loh E, Massie BM, O'Connor CM, Rich MW, Stevenson LW, Young J, Krumholz HM. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002;8:136-141.
3. Krumholz HM, Chen YT, Vaccarino V, Wang Y, Radford MJ, Bradford WD, Horwitz RI. Correlates and impact on outcomes of worsening renal function in patients ≥65 years of age with heart failure. Am J Cardiol. 2000;85:1110-1113.
4. Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, O'Connor CM, Rich MW, Stevenson LW, Wang Y, Young JB, Krumholz HM. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004;147:331-338.
5. Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, Loh E, Massie BM, Rich MW, Stevenson LW, Young JB, Krumholz HM. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61-67.
6. Shlipak MG, Massie BM. The clinical challenge of cardiorenal syndrome. Circulation. 2004;110:1514-1517.
7. Kittleson M, Hurwitz S, Shah MR, Nohria A, Lewis E, Givertz M, Fang J, Jarcho J, Mudge G, Stevenson LW. Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. J Am Coll Cardiol. 2003;41:2029-2035.
8. Burger AJ. A review of the renal and neurohormonal effects of B-type natriuretic peptide. Congest Heart Fail. 2005;11:30-38.
9. Jensen KT, Eiskjaer H, Carstens J, Pedersen EB. Renal effects of brain natriuretic peptide in patients with congestive heart failure. Clin Sci (Lond). 1999;96:5-15.
10. Wang DJ, Dowling TC, Meadows D, Ayala T, Marshall J, Minshall S, Greenberg N, Thattassery E, Fisher ML, Rao K, Gottlieb SS. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation. 2004;110:1620-1625.
11. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Cardiovascular and Renal Drugs Advisory Committee. Transcript of the 92nd meeting of the Cardiovascular and Renal Drugs Advisory Committee, May 25, 2001. Available at: http://www.fda.gov/ ohrms/dockets/ac/01/transcripts/3749t2.rtf. Accessed February 14, 2005.
12. Karkowsky AM. NDA 20-920. Natricore® (nesiritide). FDA medical officer review. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/ 3749b2_02_02-FDA-Medical%20Review.pdf. Accessed February 14, 2005.
13. Karkowsky AM. NDA 20-920. Natricore® (nesiritide). Addendum #1. FDA medical officer review. Available at: http://www.fda.gov/ohrms/dockets/ac/ 01/briefing/3749b2_02_03-FDA-Medical%20Review%20Addendum-01.PDF. Accessed February 14, 2005.
14. Scios, Inc. Prescribing information: Intravenous B-type natriuretic peptide (BNP) Natrecor® (nesiritide). 20030301. Available at: http://www.sciosinc. com/pdf/natrecorpi_final.pdf. Accessed February 14, 2005.
15. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Is nesiritide associated with renal injury in patients with acutely decompensated heart failure? Circulation. 2004;110:111-515. Abstract.
16. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency. Note for guidance on clinical investigation of medicinal products for the treatment of cardiac failure. Addendum on acute cardiac failure. Available at: http://www.emea.eu.int/pdfs/human/ewp/298603en.pdf. Accessed February 14, 2005.
17. Berndt ER. To inform or persuade? Direct-to-consumer advertising of prescription drugs. N Engl J Med. 2005;352:325-328.